4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis

Details for Australian Patent Application No. 2012202172 (hide)

Owner Novartis AG

Inventors Mogi, Muneto; Iwaki, Yuki; Yasoshima, Kayo; Umemura, Ichiro; Yamada, Ken; Imase, Hidetomo; Kawanami, Toshio; Qin, Hongbo

Agent Davies Collison Cave

Pub. Number AU-A-2012202172

Parent 2008324243

Filing date 13 April 2012

Wipo publication date 3 May 2012

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/5377 (2006.01)

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

3 May 2012 Application Open to Public Inspection

  Published as AU-A-2012202172

3 May 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012202173-System and method for processing a transaction document including one or more financial transaction entries

2012202171-System and method for reading data from a plurality of chips comprising an RFID tag